SUNRIDGE MEDICAL • SCOTTSDALE, ARIZONA
Alternative Lymphoma Treatment & Integrative Lymphoma Care in Scottsdale, Arizona
A More Individualized Approach to Hodgkin and Non-Hodgkin Lymphoma
A lymphoma diagnosis can be confusing because “lymphoma” is not one disease.
A person with slow-growing follicular lymphoma may appropriately be observed for a period of time, while someone with diffuse large B-cell lymphoma may need treatment quickly. Hodgkin lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma and other subtypes can require completely different strategies.
That is why a serious conversation about alternative lymphoma treatment has to begin with one question:
What exact lymphoma does this patient have—and what does that biology mean for the decisions that need to be made now?
At Sunridge Medical in Scottsdale, Arizona, we see patients at many different points in the lymphoma journey: immediately after diagnosis, during conventional treatment, after remission, after relapse, and after one or more therapies have stopped working.
Our role is not to treat every lymphoma as though it were the same disease. An individualized review can consider the pathology, immunophenotype, stage, molecular findings, previous treatments, current symptoms, treatment tolerance, nutritional status, medications, other medical conditions and the patient’s priorities.
The objective is to understand the entire case and help the patient make the next decision from a position of better information.
TERMINOLOGY MATTERS
What Does “Alternative Lymphoma Treatment” Actually Mean?
Patients who search for alternative lymphoma treatment are often looking for very different things.
Some want additional support while receiving chemotherapy, antibody therapy or immunotherapy. Some are trying to understand whether a less aggressive approach is appropriate. Others have relapsed lymphoma and want to know whether meaningful conventional, investigational or integrative options remain.
Complementary care generally refers to approaches used alongside established lymphoma treatment. Alternative treatment usually means using an approach in place of established treatment. Integrative oncology combines conventional treatment with evidence-informed supportive strategies while considering the whole patient.1
For lymphoma, this distinction is especially important. Some lymphomas are highly curable with established therapy. Others can behave more like chronic illnesses. Still others may require treatment sequencing across several different classes of therapy.
Sunridge Medical’s approach is not “natural versus conventional.” It is: What does the evidence show, what does this lymphoma require, and what additional support makes sense for this patient?
UNDERSTANDING LYMPHOMA
Lymphoma Is a Family of Blood Cancers, Not a Single Diagnosis
Lymphoma begins in lymphocytes, immune-system cells that normally help protect the body from infection.
The two broad categories are Hodgkin lymphoma and non-Hodgkin lymphoma (NHL), but within those groups are many biologically distinct diseases.
The American Cancer Society estimates approximately 79,320 new cases of non-Hodgkin lymphoma and 19,970 deaths in the United States in 2026. Hodgkin lymphoma accounts for an estimated 8,920 new cases and 1,100 deaths in 2026.2
Those combined statistics hide enormous differences between subtypes. Some lymphomas are slow-growing and may not need immediate therapy. Others can grow rapidly but remain potentially curable with appropriately selected treatment.
Hodgkin Lymphoma
Classic Hodgkin lymphoma has a distinctive biology and is commonly treated with chemotherapy and/or immunotherapy, sometimes with radiation. Modern regimens can produce high rates of disease control even in advanced-stage disease.4
B-Cell Non-Hodgkin Lymphoma
B-cell lymphomas make up about 85% of NHL in the United States.5 They include diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma and others.
T-Cell and NK-Cell Lymphomas
These are less common and include several biologically distinct entities. Their treatment can differ substantially from the treatment of common B-cell lymphomas.7
Indolent vs. Aggressive Lymphoma
An indolent lymphoma may grow slowly for years, while an aggressive lymphoma can progress quickly. “Aggressive” does not automatically mean hopeless: many aggressive lymphomas are treated with curative intent.
The Pathology Report Matters More in Lymphoma Than Many Patients Realize
With lymphoma, identifying the exact subtype can determine the entire treatment strategy.
A diagnosis may require lymph-node or tissue biopsy followed by specialized pathology testing. Depending on the case, that can include immunohistochemistry, flow cytometry, cytogenetic testing, FISH and molecular studies.
Imaging such as PET/CT or CT may then help define the extent of disease, while laboratory testing can provide information about blood counts, organ function, LDH and other clinical factors.
For difficult, unusual or relapsed cases, expert hematopathology review can be worth considering before a major treatment decision is made.
Important Questions to Ask About the Diagnosis
- What is the exact lymphoma subtype?
- Is it B-cell, T-cell, NK-cell or Hodgkin lymphoma?
- Is it indolent or aggressive?
- What does the immunophenotype show?
- Are there important molecular, cytogenetic or FISH findings?
- Has the pathology been reviewed by a hematopathologist experienced in lymphoma?
- What is the stage?
- Is there bulky disease or involvement outside lymph nodes?
- What clinical risk factors affect prognosis or treatment selection?
A CRITICAL DISTINCTION
Stage 4 Lymphoma Does Not Mean the Same Thing as Stage 4 Solid-Tumor Cancer
The words Stage IV can be terrifying, especially for someone familiar with Stage IV pancreatic, lung or colorectal cancer.
Lymphoma is different.
Because lymphocytes naturally travel throughout the body, lymphoma staging does not carry exactly the same meaning as metastatic staging in many solid tumors.
Some advanced-stage lymphomas—including Hodgkin lymphoma and several aggressive B-cell lymphomas—may still be treated with curative intent. Indolent Stage IV lymphoma can sometimes be managed for many years and may not require immediate treatment if it is not causing problems.36
The exact subtype and biology often matter more than the stage number alone.
Sometimes the Right Treatment Is Not to Treat Immediately
This can be one of the most surprising concepts for patients newly diagnosed with lymphoma.
Certain indolent B-cell lymphomas can sometimes be safely observed when the patient has low disease burden and no treatment-triggering symptoms or complications. The National Cancer Institute includes surveillance or watchful waiting among established management options for selected indolent non-Hodgkin lymphomas.6
That does not mean the cancer is being ignored. It means the potential benefit of immediate treatment may not outweigh the disadvantages of starting treatment before it is necessary.
A second opinion can be valuable when a patient is unsure whether observation is truly appropriate—or whether there are signs that treatment should begin.
MODERN LYMPHOMA TREATMENT
Conventional Lymphoma Treatment Has Changed Dramatically
A credible discussion of alternative lymphoma treatment should accurately explain what modern hematology can offer.
Depending on the subtype, stage and treatment history, established lymphoma treatment may include chemotherapy, monoclonal antibodies, antibody-drug conjugates, immunotherapy, targeted therapy, radiation therapy, stem-cell transplantation, CAR T-cell therapy, bispecific antibodies or active surveillance.34
The correct treatment is not simply “chemotherapy” or “no chemotherapy.” The regimen and sequence should match the specific disease.
Diffuse Large B-Cell Lymphoma: Why First-Line Treatment Matters
Diffuse large B-cell lymphoma (DLBCL) is one of the most common aggressive lymphomas.
For decades, R-CHOP was the dominant first-line regimen. In the phase III POLARIX trial, replacing vincristine with the antibody-drug conjugate polatuzumab vedotin produced a statistically significant improvement in progression-free survival with pola-R-CHP compared with R-CHOP in previously untreated intermediate- and high-risk DLBCL.8
Five-year follow-up has provided longer-term information on this strategy and continues to inform treatment selection for appropriate patients.9
The point is not that every DLBCL patient should receive the same regimen. Age, cardiac function, disease biology, risk features, comorbidities and other factors matter.
For a potentially curable aggressive lymphoma, delaying effective treatment while trying an unproven replacement therapy can have real consequences.
Advanced Hodgkin Lymphoma: Immunotherapy Has Changed the Front Line
Hodgkin lymphoma is another example of why patients should not assume that older descriptions of lymphoma treatment still represent current care.
The randomized phase III SWOG S1826 trial compared nivolumab plus AVD with brentuximab vedotin plus AVD in patients with newly diagnosed Stage III or IV classic Hodgkin lymphoma.
Nivolumab plus AVD produced significantly longer progression-free survival, with a 2-year progression-free survival of approximately 92% compared with approximately 83% in the brentuximab-AVD group.10
That is not a reason for every patient to receive nivolumab. It is a reason to make sure that treatment decisions are based on current evidence rather than an outdated understanding of what lymphoma therapy looks like.
Relapsed or Refractory Lymphoma: The Timing of the Next Decision Matters
When lymphoma does not respond to initial therapy or comes back after treatment, the next decision can depend heavily on subtype, timing of relapse, previous treatment and patient fitness.
For large B-cell lymphoma that is refractory to first-line therapy or relapses early, CAR T-cell therapy has moved earlier in the treatment sequence.
In the phase III ZUMA-7 trial, axicabtagene ciloleucel produced substantially longer event-free survival than standard salvage chemotherapy followed by autologous stem-cell transplant in eligible patients.11 Longer follow-up also demonstrated an overall-survival advantage.12
Bispecific antibodies and other newer therapies have also expanded treatment possibilities for several relapsed B-cell lymphomas.3
A patient with relapsed lymphoma should not assume that “chemotherapy failed, so there are no options.” The treatment landscape may be very different from what it was even a few years ago.
What Should Be Reassessed When Lymphoma Comes Back?
- Confirm the diagnosis. Has the disease been re-biopsied when appropriate?
- Look for transformation. An indolent lymphoma can sometimes transform into a more aggressive lymphoma.
- Review timing. Early relapse can lead to different treatment choices than relapse years later.
- Review every previous regimen. What worked, what failed and what caused unacceptable toxicity?
- Review current organ function and performance status.
- Ask whether transplant, CAR T-cell therapy or a bispecific antibody should be evaluated.
- Ask about clinical trials.
- Reassess symptoms, nutrition, infection risk and treatment tolerance.
AN IMPORTANT INTEGRATIVE-ONCOLOGY POINT
Lymphoma Is a Cancer of Immune Cells—So “Boost the Immune System” Is Too Simplistic
Many alternative-cancer websites describe every treatment as an “immune booster.” That language is particularly problematic in lymphoma.
Lymphoma itself arises from cells of the immune system. Modern lymphoma treatments can also deliberately alter B cells, T cells and other immune pathways.
A thoughtful integrative plan therefore should not be based on indiscriminately stimulating the immune system.
Instead, the goals may include supporting nutrition, physical function, sleep, hydration, symptom control and treatment tolerance while carefully reviewing supplements and other therapies for potential interactions.
Supporting the patient is not the same thing as indiscriminately “boosting” immune activity.
Where Integrative Lymphoma Care Can Fit
Integrative care should have a defined purpose.
Depending on the patient’s situation, goals may include:
- Supporting nutritional status
- Maintaining strength and lean body mass
- Addressing fatigue
- Supporting sleep
- Helping manage stress and anxiety
- Supporting hydration
- Addressing nausea, appetite changes or bowel symptoms
- Helping patients remain physically active when medically appropriate
- Reviewing supplements for interactions with lymphoma treatment
- Supporting recovery after intensive treatment
- Helping patients navigate prolonged treatment or surveillance
- Coordinating supportive care with the hematology/oncology plan when appropriate
Evidence from hematologic-cancer studies suggests that appropriately prescribed exercise is generally feasible and may improve outcomes such as fatigue, depression and physical function, although the strength of evidence varies by population and outcome.13
Broader integrative-oncology guidelines also support selected nonpharmacologic approaches for symptoms such as anxiety and depression in people with cancer.14
Integrative Care During Lymphoma Treatment
Patients receiving lymphoma therapy may experience very different side effects depending on the regimen.
Potential concerns can include fatigue, nausea, appetite loss, neuropathy, infections, low blood counts, mouth sores, sleep disruption, steroid-related symptoms and loss of physical conditioning.
A patient receiving an anti-CD20 antibody, chemotherapy, checkpoint inhibitor, CAR T-cell therapy or stem-cell transplant may also have very different infection risks and immune considerations.
That is why integrative therapies should be reviewed in the context of the exact treatment regimen rather than added from a generic lymphoma protocol.
Natural Does Not Mean Interaction-Free
Supplements and botanical products are biologically active. That is why people use them—and also why they can potentially interact with treatment.
In lymphoma, interactions may be especially important when a patient is receiving immunotherapy, cytotoxic chemotherapy, anticoagulants, transplant-related medications or therapies that affect liver metabolism and blood counts.
A responsible integrative plan should include a complete medication and supplement review.
We do not recommend adding a long list of supplements simply because someone has lymphoma.
Common Lymphoma Symptoms
Lymphoma can present in many ways, and some patients have few symptoms at diagnosis.
Symptoms that may occur include:
- Painless enlargement of lymph nodes
- Unexplained fever
- Drenching night sweats
- Unintentional weight loss
- Persistent fatigue
- Itching
- Abdominal fullness or discomfort
- Shortness of breath or cough in some cases
- Frequent infections or abnormal blood counts in some subtypes
Fever, drenching night sweats and significant unexplained weight loss are often referred to as B symptoms and can be clinically important in staging and treatment planning.
None of these symptoms proves that a person has lymphoma. Persistent or unexplained symptoms deserve medical evaluation.
Do Not Let a Generic Survival Statistic Define an Individual Case
Lymphoma survival statistics can be misleading when different diseases are combined.
The American Cancer Society reports an overall 5-year relative survival rate of about 74% for non-Hodgkin lymphoma, but outcomes differ substantially by subtype. For example, reported 5-year relative survival is much higher for follicular lymphoma than for DLBCL when all stages are combined.15
Even those numbers do not tell an individual patient what will happen. Age, subtype, molecular biology, response to treatment, disease burden, treatment eligibility and many other factors can materially change prognosis.
The diagnosis “lymphoma” is too broad to predict an individual patient’s future.
THE SUNRIDGE MEDICAL APPROACH
What Makes a Lymphoma Consultation at Sunridge Different?
The first question is not, “What alternative treatment do we give lymphoma?”
The better question is: What does this patient’s lymphoma require, what opportunities may exist, and what can we do to support the patient through the plan?
The Diagnosis
What exact subtype is present? Has the pathology been adequately characterized? Is expert review warranted?
The Disease
Is it indolent or aggressive? What is the stage? Is treatment needed now? Is there evidence of transformation?
Previous Treatment
What has already been used, how well did it work, and why was it stopped?
The Patient
What is happening with nutrition, fatigue, infections, sleep, pain, neuropathy, exercise capacity, medications and overall function?
The Next Decision
Is the immediate issue observation, first-line treatment, supportive care, relapse, transplant eligibility, CAR T-cell evaluation, clinical trials or another specialist review?
Why a Second Opinion Can Matter in Lymphoma
A second opinion does not mean the original hematologist is wrong.
Sometimes it confirms that the existing plan is exactly what should be done.
In other situations, another review may identify a question worth pursuing:
- Is the subtype correct?
- Should the pathology be reviewed again?
- Does an indolent lymphoma actually need treatment now?
- Is a rapidly growing lymphoma being treated quickly enough?
- Should a newer frontline regimen be considered?
- Has an indolent lymphoma transformed?
- After relapse, should transplant or CAR T-cell therapy be evaluated?
- Are bispecific antibodies or clinical trials relevant?
- Could treatment toxicity be better supported?
- Are supplements or complementary therapies interacting with treatment?
The value of another review is not disagreement. It is reducing the chance that an important option or detail has been overlooked.
You Do Not Have to Wait Until Every Conventional Treatment Has Failed
Many patients historically sought alternative lymphoma treatment only after exhausting every other option.
Sunridge Medical also sees patients much earlier in the process.
Patients may seek an integrative consultation:
- Immediately after diagnosis
- While waiting for final pathology or staging
- Before starting first-line treatment
- During chemotherapy or immunotherapy
- During watchful waiting
- After achieving remission
- When treatment side effects are difficult
- At the time of relapse
- After refractory disease
- While considering transplant, CAR T-cell therapy or a clinical trial
There can be an advantage to addressing nutrition, treatment tolerance, physical function and supportive-care needs before a patient becomes severely depleted.
What to Bring to a Lymphoma Consultation
The more complete the medical record, the more useful the consultation can be.
- Pathology report
- Original biopsy report
- Flow cytometry and immunohistochemistry results
- FISH, cytogenetic or molecular testing
- PET/CT and CT reports
- Actual imaging files when available
- Bone marrow biopsy results if performed
- CBC, chemistry panel and LDH trends
- Treatment records
- Radiation records
- Transplant or cellular-therapy records if applicable
- Current medication list
- Current supplement list
- A timeline of diagnosis, response, remission and relapse
Questions Every Lymphoma Patient Should Be Asking
- What exact lymphoma subtype do I have?
- Is it indolent or aggressive?
- Do I actually need treatment now?
- What is the goal of treatment—cure, durable remission, disease control or symptom relief?
- What evidence supports the regimen being recommended?
- Are there newer treatment options relevant to my subtype?
- How will we determine whether treatment is working?
- What happens if the lymphoma does not respond?
- If it relapses, does the timing of relapse change my options?
- Should I be evaluated for transplant, CAR T-cell therapy, a bispecific antibody or a clinical trial?
- What can be done to reduce or manage treatment side effects?
- Are any supplements I take capable of interacting with therapy?
Why Patients Travel to Sunridge Medical in Scottsdale, Arizona
Patients come to Sunridge Medical because they want more time to understand the complete picture.
Some want an evidence-informed integrative plan while continuing treatment with their hematologist. Some want help managing treatment-related symptoms and maintaining strength. Others are facing relapse and want another review of what may still be available.
We believe patients should be able to discuss conventional, integrative and emerging treatment options without being forced into an artificial choice between “standard” and “alternative” medicine.
The conversation begins with the individual patient and the exact lymphoma—not with a predetermined protocol.
When Lymphoma Feels Overwhelming, Focus on the Next Decision
A new lymphoma diagnosis can create a flood of information.
You do not have to solve every future treatment decision today.
The immediate question may be confirming the subtype. For another patient it may be deciding whether treatment is needed now. For someone else it may be determining what to do after relapse.
Good lymphoma care is often a sequence of well-informed decisions.
Hope is not pretending that every lymphoma is easy to treat. Hope is making sure the diagnosis is right, the current evidence is understood, and legitimate options have not been overlooked.
Speak With the Sunridge Medical Patient Care Team
If you or someone you love has been diagnosed with Hodgkin lymphoma or non-Hodgkin lymphoma, Sunridge Medical can review your situation and help you understand the questions that deserve attention now.
We work with patients who are newly diagnosed, receiving treatment, being observed, in remission, facing relapse or looking for another perspective after previous treatment.
Sunridge Medical • Scottsdale, Arizona
FREQUENTLY ASKED QUESTIONS
Frequently Asked Questions About Alternative Lymphoma Treatment
Can lymphoma be cured?
Some lymphomas are highly curable, including many cases of Hodgkin lymphoma and aggressive B-cell lymphoma. Other lymphomas, particularly some indolent types, may behave more like chronic illnesses that can be controlled for long periods. The exact subtype is essential.
Can Stage 4 lymphoma be treated?
Yes. Stage IV lymphoma does not carry the same meaning as Stage IV disease in many solid tumors. Some advanced lymphomas can still be treated with curative intent, while indolent Stage IV lymphomas may sometimes be observed or treated intermittently over many years.
What is the best alternative lymphoma treatment?
There is no single alternative lymphoma treatment proven to work for every lymphoma. A responsible integrative strategy starts with the exact diagnosis and does not replace potentially curative treatment with an unproven universal protocol.
Can an indolent lymphoma be watched without treatment?
Yes, in selected patients. Active surveillance or watchful waiting is an established strategy for certain indolent lymphomas when treatment is not yet indicated. Monitoring should be structured and medically supervised.
What is diffuse large B-cell lymphoma?
DLBCL is a common aggressive B-cell non-Hodgkin lymphoma. It usually requires prompt treatment, but it is also potentially curable in many patients.
What is follicular lymphoma?
Follicular lymphoma is a common indolent B-cell lymphoma. Its course varies widely. Some patients need treatment at diagnosis while others can be observed until treatment criteria are met.
What happens if lymphoma comes back?
Relapsed lymphoma should be reassessed based on subtype, timing of relapse, previous treatment and current health. Options can include additional systemic therapy, stem-cell transplantation, CAR T-cell therapy, bispecific antibodies, targeted therapies and clinical trials depending on the disease.
Is CAR T-cell therapy an option for lymphoma?
CAR T-cell therapy is an established option for several B-cell lymphomas in specific clinical situations. In some large B-cell lymphomas it can be considered as early as second-line treatment when disease is refractory or relapses early.
Can integrative care be used during chemotherapy or immunotherapy?
Yes, but the plan should be built around the exact treatment regimen. Integrative care may focus on nutrition, physical function, sleep, symptom management, stress and treatment tolerance while potential interactions are carefully reviewed.
Should I take immune-boosting supplements for lymphoma?
Not automatically. Lymphoma is a cancer of immune-system cells, and lymphoma therapies often alter immune pathways. Supplements should be reviewed individually rather than added simply because they are marketed as immune boosters.
Does Sunridge Medical replace my hematologist or lymphoma specialist?
Not necessarily. Many patients use integrative care alongside conventional hematology/oncology. A coordinated approach can allow supportive needs to be addressed while specialized lymphoma treatment continues with the appropriate oncology team.
When should I get a second opinion?
A second opinion can be useful after diagnosis, before starting a major treatment, when observation is being considered, when pathology is unusual, at relapse, or when the current plan is unclear. You do not have to wait until all treatments have failed.
SOURCES
References
- National Cancer Institute. Complementary and Alternative Medicine (CAM). Definitions of complementary, alternative and integrative medicine.
- American Cancer Society. Cancer Facts & Figures 2026. U.S. estimates for non-Hodgkin and Hodgkin lymphoma.
- National Cancer Institute. Non-Hodgkin Lymphoma Treatment (PDQ®).
- National Cancer Institute. Hodgkin Lymphoma Treatment (PDQ®).
- American Cancer Society. Types of B-cell Lymphoma.
- National Cancer Institute. Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®).
- National Cancer Institute. Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®).
- Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. New England Journal of Medicine. 2022;386:351-363. PMID: 34904799.
- Morschhauser F, et al. Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Diffuse Large B-Cell Lymphoma. 2025. PMID: 40991874.
- Herrera AF, LeBlanc M, Castellino SM, et al. Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma. New England Journal of Medicine. 2024. PMID: 39413375.
- Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. New England Journal of Medicine. 2022;386:640-654. PMID: 34891224.
- Westin JR, et al. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. New England Journal of Medicine. 2023. PMID: 37272527.
- Knips L, Bergenthal N, Streckmann F, et al. Aerobic Physical Exercise for Adult Patients With Haematological Malignancies. Cochrane Database of Systematic Reviews. 2019. PMID: 30702150.
- Carlson LE, Ismaila N, Addington EL, et al. Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults With Cancer: Society for Integrative Oncology–ASCO Guideline. Journal of Clinical Oncology. 2023;41(28):4562-4591. PMID: 37582238.
- American Cancer Society. Survival Rates and Factors That Affect Prognosis for Non-Hodgkin Lymphoma.
